Omega Diagnostics appears to be on course to gain a CE Mark for its Visitect CD4 HIV diagnostic test by the end of March.
Visitect CD4 has significant potential with the main customers non-government organisations working in Africa and Asia.
Small orders have already been secured for the test from Indonesia, Moldova and Papua New Guinea. Ethics approval has been gained from the Nigerian authorities for a performance evaluation. Nigeria could be the largest potential market for the test.
There is nothing in the forecasts for Visitect CD4 revenues in the year to March 2019 and there are no 2019-20 forecasts, although there are expected to be meaningful revenues for the test next year.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.